Illinois Tool Works Inc. vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Illinois Tool Works Inc. trades at $263.26 (market cap $74.38B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.27 (market cap $2.28B). The key difference: Illinois Tool Works Inc. is far larger — about 32.6× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Illinois Tool Works Inc. pays a 2.63% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| ITW | SLS | |
|---|---|---|
Market Cap | $74.38B | $2.28B |
Volume | 1,125,477 | 3,128,960 |
Sector | Industrials | Health |
52-Week High | $299.60 | $15.46 |
52-Week Low | $241.07 | $1.39 |
Typical Hold Time | 67 Days | — |
Enterprise Value | $83.23B | $2.15B |
Dividend Yield | 2.63% | — |
Signals from Pluang's Aura AI — not financial advice
ITW trades at $264.71, down 0.91% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 19.39% net margins and 104.65% ROE, though valuation multiples appear elevated. Recent dividend increase to $1.72 reinforces its Dividend King status with 59 years of consecutive growth. Operating cash flow remains robust at $3.13B, supporting continued shareholder returns.
Outlook remains mixed with analyst consensus target of $280.14 offering 5.8% upside, but technical indicators signal near-term pressure. The company faces headwinds in automotive and foodservice segments while maintaining strong organic growth prospects. Debt levels have increased to 55.54% of assets, requiring monitoring amid rising interest rates.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →